Menu
Search
|

Menu

Close
X

Zafgen Inc ZFGN.OQ (NASDAQ Stock Exchange Global Select Market)

9.88 USD
+0.27 (+2.81%)
As of Nov 16
chart
Previous Close 9.61
Open 9.53
Volume 47,816
3m Avg Volume 75,967
Today’s High 9.97
Today’s Low 9.26
52 Week High 12.35
52 Week Low 3.41
Shares Outstanding (mil) 36.87
Market Capitalization (mil) 401.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.563
FY17
-1.897
FY16
-2.121
FY15
-2.767
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
3.87
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
19.70
13.84
LT Debt to Equity (MRQ)
vs sector
16.21
9.93
Return on Investment (TTM)
vs sector
-57.03
13.58
Return on Equity (TTM)
vs sector
-62.00
15.11

EXECUTIVE LEADERSHIP

Peter Barrett
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Jeffrey Hatfield
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Patricia Allen
Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Dennis Kim
Chief Medical Officer, Since 2011
Salary: $367,500.00
Bonus: --
Brian McVeigh
Chief Business Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

175 Portland St Fl 4
BOSTON   MA   02114-1713

Phone: +1617.6224003

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.

SPONSORED STORIES